Intended for healthcare professionals


Migraine: NICE recommends further prevention option

BMJ 2020; 371 doi: (Published 19 October 2020) Cite this as: BMJ 2020;371:m4052
  1. Elisabeth Mahase
  1. The BMJ

Galcanezumab, a new migraine drug, has been recommended by the National Institute for Health and Care Excellence as part of draft guidance.1

Published on 15 October, the guidance said that galcanezumab (marketed by Eli Lilly as Emgality) can be used to prevent migraine in adults who have at least four days with migraine each month and in whom at least three previous preventive treatments …

View Full Text

Log in

Log in through your institution


* For online subscription